Suchergebnisse - (Subject:"Siltuximab")

PubPharm (21)

1

Advances in clinical outcomes : What we have learned during the COVID-19 pandemic

enthalten in: The Journal of allergy and clinical immunology | 2022

von Al-Musa, A. | LaBere, B. | Habiballah, S. | +2

2

Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition : A pediatric case series

enthalten in: Pediatric blood & cancer | 2021

von Lust, H. | Gong, S. | Remiker, A. | +1

3

Experience with the use of siltuximab in patients with SARS-CoV-2 infection

enthalten in: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia | 2021

von Meira, F. | Albiach, L. | Carbonell, C. | +32

4

Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease

enthalten in: Expert opinion on investigational drugs | 2020

von Zhou, Z. | Price, C.

5

Involvement of interleukin 6 in SARS-CoV-2 infection : siltuximab as a therapeutic option against COVID-19

enthalten in: European journal of hospital pharmacy : science and practice | 2020

von Palanques-Pastor, T. | López-Briz, E. | Poveda Andrés, J.

6

Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID) : A structured summary of a study protocol for a randomised controlled trial

enthalten in: Trials | 2020

von Maes, B. | Bosteels, C. | De Leeuw, E. | +14

ErratumIn: Trials. 2020 Jun 22;21(1):556. - PMID 32571394

7

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

8

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

enthalten in: Hematology. American Society of Hematology. Education Program | 2018

von Fajgenbaum, D.

9

The Role of Interleukin-6 in Castleman Disease

enthalten in: Hematology/oncology clinics of North America | 2018

von Yoshizaki, K. | Murayama, S. | Ito, H. | +1

10

JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease

enthalten in: JAMA dermatology | 2017

von Patel, M. | Ikeda, S. | Pilat, S. | +1

CommentIn: JAMA Dermatol. 2017 May 1;153(5):381-382. - PMID 28241212